Drugs / AZX100
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00892723 | May 2009 → Sep 2010 | keloid formation | Capstone Therapeutics | Completed | Missed primary |
| Phase 2 | NCT00825916 | Mar 2009 → Jul 2010 | keloid formation | Capstone Therapeutics | Completed | Missed primary |
| Phase 2 | NCT00811577 | Jan 2009 → Dec 2010 | — | Capstone Therapeutics | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZX100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00811577 ↗ |
| Route | Other | “intradermally at the site of the keloid scar removal” NCT00892723 ↗ |